Skip to main content

Aerie Pharmaceuticals Value Stock - Dividend - Research Selection

Aerie Pharmaceuticals

ISIN: US00771V1089, WKN: A1W7RL

Market price date: 25.09.2020
Market price: 11,21 USD




Aerie Pharmaceuticals Fundamental data and company key figures of the share

Annual reports in USD
Key figures 10-09-2020
Cash flow
Net operating cash flow -150.430.000
Capital Expenditures -17.793.000
Free cash flow -168.223.008
Balance sheet
Total Equity 166.950.000
Liabilities & Shareholders equity 452.608.000
Income statement
Net income -199.581.000
Eps (diluted) -4,390
Diluted shares outstanding 45.462.600
Net sales/revenue 69.888.000

Fundamental ratios calculated on: 25-09-2020

Ratios
Key figures 25-09-2020
Cash flow
P/C -3,39
   
P/FC -3,03
Balance sheet
ROI-44,10
ROE36,89
Income statement
P/E-2,55
Div. Yield0,00%
P/B3,05
P/S7,29


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolAERI
Market Capitalization509.635.744,00 USD
CountryUnited States
IndicesNASDAQ Comp.
Sectors
Raw Data SourceUS GAAP in Millionen USD
Stock Split
Internethttp://www.aeriepharma.com


Description of the company

Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, dry eye, retinal diseases, and other eye diseases. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. The company is also developing AVX-012, a clinical-stage dry eye product candidate; and AR-1105 and AR-13503 sustained-release implants for treating retinal diseases. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, http://www.aeriepharma.com